.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD09_PioglitazoneAndAloglipti.PioglitazoneAndAloglipti .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD09_PioglitazoneAndAloglipti.PioglitazoneAndAloglipti| name: | PioglitazoneAndAlogliptin |
| ATC code: | A10BD09 | route: | oral |
| n-compartments | 1 |
Pioglitazone and alogliptin is a fixed-dose combination antidiabetic medication used in the management of type 2 diabetes mellitus when diet, exercise, and either agent alone do not provide adequate glycemic control. Pioglitazone is a thiazolidinedione that improves insulin sensitivity, while alogliptin is a DPP-4 inhibitor that increases levels of incretin hormones. The combination is approved for use in several countries including those in the EU and US.
Estimated pharmacokinetic parameters for healthy adult subjects based on separate published PK data for pioglitazone and alogliptin, as no population PK study of the fixed-dose combination exists.